MA35459B1 - Composés et compositions pouvant être utilisés en tant qu'inhibiteurs de la kinase c-kit - Google Patents

Composés et compositions pouvant être utilisés en tant qu'inhibiteurs de la kinase c-kit

Info

Publication number
MA35459B1
MA35459B1 MA36863A MA36863A MA35459B1 MA 35459 B1 MA35459 B1 MA 35459B1 MA 36863 A MA36863 A MA 36863A MA 36863 A MA36863 A MA 36863A MA 35459 B1 MA35459 B1 MA 35459B1
Authority
MA
Morocco
Prior art keywords
compounds
compositions
kinase inhibitors
kit
kit kinase
Prior art date
Application number
MA36863A
Other languages
English (en)
Inventor
Vince Yeh
Xiaolin Li
Xiaodong Liu
Jon Loren
Valentina Molteni
Juliet Nabakka
Bao Nguyen
Hank Michael James Petrassi
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of MA35459B1 publication Critical patent/MA35459B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des composés de formule (i) et (ii) et des compositions pharmaceutiques en contenant, pouvant être utilisés en tant qu'inhibiteurs des protéines kinases, ainsi que des méthodes d'utilisation desdits composés à des fins de traitement, d'amélioration ou de prévention d'une affection associée à une activité anormale ou dérégulée des kinases. Dans certains modes de réalisation, l'invention concerne des méthodes d'utilisation desdits composés à des fins de traitement, d'amélioration ou de prévention des maladies ou affections impliquant une activation anormale des kinases c-kit ou c-kit et pdgfr (pdgfr±, pdgfr²).
MA36863A 2011-09-01 2014-03-28 Composés et compositions pouvant être utilisés en tant qu'inhibiteurs de la kinase c-kit MA35459B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161530028P 2011-09-01 2011-09-01
PCT/US2012/052621 WO2013033070A1 (fr) 2011-09-01 2012-08-28 Composés et compositions pouvant être utilisés en tant qu'inhibiteurs de la kinase c-kit

Publications (1)

Publication Number Publication Date
MA35459B1 true MA35459B1 (fr) 2014-09-01

Family

ID=46829898

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36863A MA35459B1 (fr) 2011-09-01 2014-03-28 Composés et compositions pouvant être utilisés en tant qu'inhibiteurs de la kinase c-kit

Country Status (41)

Country Link
US (1) US9199981B2 (fr)
EP (1) EP2751102B1 (fr)
JP (1) JP6117208B2 (fr)
KR (1) KR101959590B1 (fr)
CN (1) CN103764653B (fr)
AP (1) AP2014007494A0 (fr)
AR (1) AR087752A1 (fr)
AU (1) AU2012300248B2 (fr)
BR (1) BR112014004504B1 (fr)
CA (1) CA2845159C (fr)
CL (1) CL2014000494A1 (fr)
CO (1) CO6900140A2 (fr)
CR (1) CR20140106A (fr)
CU (1) CU20140023A7 (fr)
CY (1) CY1121695T1 (fr)
DK (1) DK2751102T3 (fr)
EA (1) EA024293B1 (fr)
ES (1) ES2732671T3 (fr)
GT (1) GT201400036A (fr)
HR (1) HRP20191140T1 (fr)
HU (1) HUE044373T2 (fr)
IL (1) IL231226A (fr)
JO (1) JOP20120246B1 (fr)
LT (1) LT2751102T (fr)
MA (1) MA35459B1 (fr)
ME (1) ME03395B (fr)
MX (1) MX342329B (fr)
MY (1) MY167245A (fr)
PE (1) PE20141033A1 (fr)
PL (1) PL2751102T3 (fr)
PT (1) PT2751102T (fr)
RS (1) RS59025B1 (fr)
SG (1) SG2014011050A (fr)
SI (1) SI2751102T1 (fr)
TN (1) TN2014000061A1 (fr)
TR (1) TR201909189T4 (fr)
TW (1) TWI543981B (fr)
UA (1) UA110841C2 (fr)
UY (1) UY34300A (fr)
WO (1) WO2013033070A1 (fr)
ZA (1) ZA201401113B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
WO2013033167A1 (fr) 2011-09-01 2013-03-07 Irm Llc Composés et compositions en tant qu'inhibiteurs de kinase c-kit
EA028722B1 (ru) * 2012-07-13 2017-12-29 Юсб Байофарма Спрл Производные имидазопиридина в качестве модуляторов активности tnf
US9815815B2 (en) 2013-01-10 2017-11-14 Pulmokine, Inc. Non-selective kinase inhibitors
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
CN111743901B (zh) 2013-10-11 2023-09-12 普尔莫凯恩股份有限公司 喷雾干燥制剂
EP3077394A1 (fr) * 2013-12-05 2016-10-12 Bayer Pharma Aktiengesellschaft Imidazo[1,2-a]pyridine-3-carboxamides aryl et hétéroaryl substitués et leur utilisation
CN103965190A (zh) * 2014-05-20 2014-08-06 定陶县友帮化工有限公司 一种咪唑并[1,2-a]吡啶-3-甲酸的合成方法
MA42293A (fr) 2015-07-02 2018-05-09 Janssen Sciences Ireland Uc Composés antibactériens
US10059708B2 (en) * 2016-04-26 2018-08-28 Northwestern University Therapeutic targeting of the interleukin 1 receptor-associated kinase 4 (IRAK4) in leukemias characterized by rearrangements in the mixed lineage leukemia gene (MLL-r)
BR112018075939A2 (pt) 2016-06-16 2019-04-09 Janssen Sciences Ireland Unlimited Company compostos heterocíclicos como antibacterianos
AU2017286368B2 (en) 2016-06-16 2021-02-25 Janssen Sciences Ireland Unlimited Company Heterocyclic compounds as antibacterials
AU2017348354B2 (en) 2016-10-27 2023-06-15 Pulmokine, Inc. Combination therapy for treating pulmonary hypertension
MA47676A (fr) 2017-03-01 2021-06-02 Janssen Sciences Ireland Unlimited Co Polythérapie
CN111039946A (zh) * 2018-10-15 2020-04-21 上海轶诺药业有限公司 一类咪唑并芳环类化合物的制备和应用
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
CA3139552A1 (fr) * 2019-05-13 2020-11-19 Novartis Ag Formes cristallines de n-(5-(5-((1r, 2s)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-2-methylphenyl) imidazo [1,2-a] pyridine-3-carboxamide
AU2020346370A1 (en) 2019-09-13 2022-05-05 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
TW202146392A (zh) * 2020-03-17 2021-12-16 日商大日本住友製藥股份有限公司 㗁二唑衍生物
JP2023534963A (ja) * 2020-07-15 2023-08-15 サード ハーモニック バイオ， インコーポレイテッド 選択的ｃ－ｋｉｔキナーゼ阻害剤の結晶質形態
US20220175740A1 (en) * 2020-11-19 2022-06-09 Novartis Ag Pharmaceutical compositions of a selective c-kit kinase inhibitor and methods for making and using same
US11744823B2 (en) 2020-11-19 2023-09-05 Third Harmonic Bio, Inc. Pharmaceutical compositions of a selective c-kit kinase inhibitor and methods for making and using same
WO2022182982A1 (fr) * 2021-02-26 2022-09-01 Third Harmonic Bio, Inc. Méthodes de traitement de maladies et de troubles médiés par la kinase c-kit à l'aide d'un inhibiteur sélectif de kinase c-kit
EP4308239A1 (fr) 2021-03-16 2024-01-24 Janssen Sciences Ireland Unlimited Company Composés antibactériens
CA3211592A1 (fr) 2021-03-17 2022-09-22 Jerome Emile Georges Guillemont Composes antibacteriens
CA3212074A1 (fr) 2021-03-17 2022-09-22 Janssen Sciences Ireland Unlimited Company Composes antibacteriens
CA3234515A1 (fr) 2021-10-28 2023-05-04 Jose Manuel Bartolome-Nebreda Amides d'imidazopyridine et composes apparentes destines a etre utilises dans le traitement d'infections bacteriennes
WO2024089170A1 (fr) 2022-10-27 2024-05-02 Janssen Sciences Ireland Unlimited Company Composés antibactériens

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9518993D0 (en) * 1995-09-16 1995-11-15 Agrevo Uk Ltd Fungicides
US20070072861A1 (en) * 2000-03-27 2007-03-29 Barbara Roniker Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders
AU2003251561A1 (en) 2002-06-20 2004-01-06 Beacon Looms, Inc. Knitted electrical conductor fabric
CA2514733A1 (fr) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Compositions pharmaceutiques a base d'un co-cristal
US7754717B2 (en) 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
US20100048539A1 (en) 2006-11-03 2010-02-25 Irm Llc Compounds and compositions as protein kinase inhibitors
KR20140009251A (ko) * 2010-11-15 2014-01-22 애브비 인코포레이티드 Ｎａｍｐｔ 및 ｒｏｃｋ 억제제
WO2013033167A1 (fr) * 2011-09-01 2013-03-07 Irm Llc Composés et compositions en tant qu'inhibiteurs de kinase c-kit
CN103930424A (zh) * 2011-09-01 2014-07-16 Irm责任有限公司 作为c-Kit激酶抑制剂的化合物和组合物
EP2751103A1 (fr) * 2011-09-01 2014-07-09 Irm Llc Composés et compositions pouvant être utilisés en tant qu'inhibiteurs de la kinase c-kit

Also Published As

Publication number Publication date
EA024293B1 (ru) 2016-09-30
CR20140106A (es) 2014-05-02
MX342329B (es) 2016-09-26
AU2012300248B2 (en) 2015-08-27
PT2751102T (pt) 2019-07-10
ES2732671T3 (es) 2019-11-25
WO2013033070A1 (fr) 2013-03-07
CO6900140A2 (es) 2014-03-20
KR101959590B1 (ko) 2019-03-18
AR087752A1 (es) 2014-04-16
NZ621092A (en) 2016-06-24
CY1121695T1 (el) 2020-07-31
MY167245A (en) 2018-08-14
SI2751102T1 (sl) 2019-08-30
LT2751102T (lt) 2019-07-10
US20130059846A1 (en) 2013-03-07
ZA201401113B (en) 2015-10-28
AU2012300248A1 (en) 2014-04-17
CU20140023A7 (es) 2014-04-24
TR201909189T4 (tr) 2019-07-22
GT201400036A (es) 2015-06-02
CL2014000494A1 (es) 2014-09-05
UA110841C2 (uk) 2016-02-25
DK2751102T3 (da) 2019-07-01
RS59025B1 (sr) 2019-08-30
PL2751102T3 (pl) 2019-09-30
SG2014011050A (en) 2014-08-28
EA201490540A1 (ru) 2014-06-30
IL231226A0 (en) 2014-04-30
CN103764653B (zh) 2015-12-02
KR20140071382A (ko) 2014-06-11
TN2014000061A1 (en) 2015-07-01
CN103764653A (zh) 2014-04-30
AP2014007494A0 (en) 2014-03-31
US9199981B2 (en) 2015-12-01
TWI543981B (zh) 2016-08-01
HUE044373T2 (hu) 2019-10-28
EP2751102B1 (fr) 2019-03-27
MX2014002482A (es) 2014-11-25
HRP20191140T1 (hr) 2019-09-20
JP2014525444A (ja) 2014-09-29
BR112014004504A2 (pt) 2017-03-28
IL231226A (en) 2017-03-30
JP6117208B2 (ja) 2017-04-19
EP2751102A1 (fr) 2014-07-09
CA2845159C (fr) 2020-11-03
PE20141033A1 (es) 2014-08-30
ME03395B (fr) 2020-01-20
TW201313716A (zh) 2013-04-01
UY34300A (es) 2013-04-05
BR112014004504B1 (pt) 2022-03-22
CA2845159A1 (fr) 2013-03-07
JOP20120246B1 (ar) 2022-03-14

Similar Documents

Publication Publication Date Title
MA35459B1 (fr) Composés et compositions pouvant être utilisés en tant qu'inhibiteurs de la kinase c-kit
MA35460B1 (fr) Composés et compositions en tant qu'inhibiteurs de kinase c-kit
MA38483A1 (fr) Inhibiteurs de l'ido
MA40290A1 (fr) Agents immunorégulateurs
MA40111A1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA45985B1 (fr) Inhibiteurs de diacylglycérol acyltransférase 2
MA37762A1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
MA37764A1 (fr) Composés n-alkyltriazole utilisés comme antagonistes de lpar
TN2014000420A1 (fr) Derives d'indole et d'indazole qui activent la mpk
MA38810B1 (fr) Inhibiteurs de rorc2 méthodes d'utilisation associées
MA38380A1 (fr) Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr)
MA34474B1 (fr) Agonistes de gpr40
MA35576B1 (fr) Nouveaux composés
MA32393B1 (fr) Composés et compositions servant d'inhibiteurs de kinases
MA31167B1 (fr) Inhibiteurs de l'activite de akt
BR112012004453A8 (pt) composto inibidor de proteína quinase, sua composição farmacêutica e seu uso
MA40955B1 (fr) 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
MA44948A1 (fr) Inhibiteurs de bace 1
MA38346A3 (fr) 2,3-benzodiazépines bicyclo- et spirocyclosubstituées
MA37765A1 (fr) Composés de pyrazole substitués utilisés comme antagonistes de lpar
MA37763A1 (fr) Difluoro-hexahydro-cyclopentaoxazinyles et difluoro-hexahydro-benzooxazinyles en tant qu'inhibiteurs de bace1
MA38410A1 (fr) Composés d'azétidinyloxyphénylpyrrolidine
MA39253A1 (fr) Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr
MA37880A1 (fr) Formulation transdermique contenant des inhibiteurs de cox
MA41174B1 (fr) Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pi3kbeta